Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time
Open accessAbstract
Background In premenopausal women with hormone receptor-positive breast cancer (BC), 5 years of tamoxifen is recommended. Little is known about reasons for interruption in this population. The aim was to estimate the incidence of tamoxifen interruption and its correlates among younger women.Patients and methods Using a prospective cohort Elippse 40 of women with BC aged ≤ 40 diagnosed between 2005 and 2008, we studied 196 women. Tamoxifen interruption was defined as two or more consecutive months without dispensed prescription of tamoxifen, based on pharmacy refill database. Two periods were studied: between tamoxifen initiation and 16 months after BC diagnosis, and between 16 and 28 months.Results Among women treated with tamoxifen, 42% interrupted within the first 2 years of treatment. During the first period, treatment interruptions were associated with a lack of understandable information about endocrine treatment and insufficient social support. During the second period, another set of factors were associated with interruption: treatment side-effects, no longer fearing cancer relapse, lack of social support, no opportunity to ask questions at the time of diagnosis, and fewer treatment modalities.Conclusions Improving information and patient-provider relationship might prevent interruption. Particular attention should be paid to women with little social support.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Published adherence rates probably underestimate true adherence because doctors and patients overestimate adherence.
“Moreover, given the challenges in measuring adherence behaviors11 and overestimation of adherence by doctors and patients, published rates are probably an underestimation of the true adherence rates.15”
From Behavioral interventions to enhance adherence to hormone therapy in breast cancer survivors: a systematic literature review (2016) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742 · see citing works
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974 · see citing works
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M. T., Cronin, W. M., Vogel, V. G., Robidoux, A., Dimitrov, N. S., Atkins, J. N., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,478 · see citing works
Tamoxifen for early breast cancer: an overview of the randomised trials
Abe, O., Bartholomeus, S., & Piccart-Gebhart, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,118 · see citing works
Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer
Berry, D. A., Cronin, K. A., Plevritis, S. K., Fryback, D. G., Clarke, L. D., Zelen, M., Mandelblatt, J. S., Yakovlev, A. Y., Habbema, J. D. F., & Feuer, E. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050518 · Cited by 2,456 · see citing works
Medication compliance and persistence: terminology and definitions
Cramer, J. A., Roy, A., Burrell, A., Fairchild, C. J., Fuldeore, M. J., Ollendorf, D. A., & Wong, P. K. (2008) · Value in Health · doi:10.1111/j.1524-4733.2007.00213.x · Cited by 2,220 · see citing works
Horne, R., & Weinman, J. (1999) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(99)00057-4 · Cited by 2,201 · see citing works
DiMatteo, M. R. (2004) · Medical Care · doi:10.1097/01.mlr.0000114908.90348.f9 · Cited by 2,169 · see citing works
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146 · see citing works
Social support and patient adherence to medical treatment: a meta-analysis.
DiMatteo, M. R. (2004) · Health Psychology · doi:10.1037/0278-6133.23.2.207 · Cited by 2,107 · cited 1× · see citing works
“Social support is known to improve adherence to medical treatment in general [27] and also to oral-based cancer treatment [28].”
BackgroundGoldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., Thurlimann, B. J. K., & Senn, H.-J. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi326 · Cited by 1,123 · see citing works
Methods for evaluation of medication adherence and persistence using automated databases
Andrade, S. E., Kahler, K. H., Frech, F. H., & Chan, K. A. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1230 · Cited by 1,077 · see citing works
Fisher, B., Dignam, J. J., Wolmark, N., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05036-9 · Cited by 1,043 · see citing works
Hershman, D. L., Kushi, L. H., Shao, T. H., Buono, D. L., Kershenbaum, A., Tsai, W., Fehrenbacher, L., Gomez, S. L., Miles, S. Q., & Neugut, A. I. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9655 · Cited by 834 · see citing works
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
Partridge, A. H., Wang, P. S., Winer, E. P., & Avorn, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.071 · Cited by 676 · see citing works
Fuhrer, R., & Rouillon, F. (1989) · Psychiatry and Psychobiology · doi:10.1017/s0767399x00001590 · Cited by 666 · see citing works
Adherence to Therapy With Oral Antineoplastic Agents
Partridge, A. H. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.9.652 · Cited by 585 · see citing works
Patient adherence and persistence with oral anticancer treatment
Ruddy, K., Mayer, E., & Partridge, A. (2009) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20004 · Cited by 569 · see citing works
McCowan, C., Shearer, J., Donnan, P. T., Dewar, J. A., Crilly, M., Thompson, A. M., & Fahey, T. P. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604758 · Cited by 343 · see citing works
Adherence to tamoxifen over the five-year course
Lash, T. L., Fox, M. P., Westrup, J., Fink, A. K., & Silliman, R. A. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9193-0 · Cited by 321 · see citing works
Owusu, C., Buist, D. S. M., Field, T. S., Lash, T. L., Thwin, S. S., Geiger, A. M., Quinn, V. P., Frost, F. J., Prout, M. N., Yood, M. U., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1022 · Cited by 304 · see citing works
Adjuvant Tamoxifen: Predictors of Use, Side Effects, and Discontinuation in Older Women
Demissie, S., Silliman, R. A., & Lash, T. L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.322 · Cited by 301 · see citing works
Fink, A. K., Gurwitz, J. H., Rakowski, W., Guadagnoli, E., & Silliman, R. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.064 · Cited by 282 · see citing works
Early discontinuation of tamoxifen
Barron, T. I., Connolly, R. M., Bennett, K., Feely, J., & Kennedy, M. J. (2007) · Cancer · doi:10.1002/cncr.22485 · Cited by 281 · see citing works
Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer
Ziller, V., Kalder, M., Albert, U., Holzhauer, W., Ziller, M., Wagner, U. A. G., & Hadji, P. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn646 · Cited by 263 · see citing works
Patient Centered Experiences in Breast Cancer: Predicting Long-Term Adherence to Tamoxifen Use
Kahn, K. L., Schneider, E. C., Malin, J. L., Adams, J. L., & Epstein, A. M. (2007) · Medical Care · doi:10.1097/01.mlr.0000257193.10760.7f · Cited by 245 · see citing works
Adherence beliefs among breast cancer patients taking tamoxifen
Grunfeld, E. A., Hunter, M. S., Sikka, P., & Mittal, S. (2004) · Patient Education and Counseling · doi:10.1016/j.pec.2004.10.005 · Cited by 245 · see citing works
Adjuvant hormonal therapy use among insured, low-income women with breast cancer
Kimmick, G., Anderson, R., Camacho, F., Bhosle, M., Hwang, W., & Balkrishnan, R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.2419 · Cited by 198 · see citing works
Baumann, C., Erpelding, M., Régat, S., Collin, J. F., & Briançon, S. (2010) · Revue d Épidémiologie et de Santé Publique · doi:10.1016/j.respe.2009.10.009 · Cited by 177 · see citing works
Mortality Impact of Less-than-Standard Therapy in Older Breast Cancer Patients
Yood, M. U., Owusu, C., Buist, D. S. M., Geiger, A. M., Field, T. S., Thwin, S. S., Lash, T. L., Prout, M. N., Wei, F., Quinn, V. P., et al. (2008) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2007.07.015 · Cited by 155 · see citing works
Burstein, H. J., Griggs, J. J., Prestrud, A. A., & Temin, S. (2010) · Journal of Oncology Practice · doi:10.1200/jop.000082 · Cited by 143 · see citing works
Insight into Barriers Against Optimal Adherence to Oral Hormonal Therapy in Women with Breast Cancer
Kirk, M. C., & Hudis, C. A. (2008) · Clinical Breast Cancer · doi:10.3816/cbc.2008.n.016 · Cited by 87 · see citing works
Pellegrini, I., Sarradon‐Eck, A., Soussan, P. B., Lacour, A., Largillier, R., Tallet, A. R., Tarpin, C., & Julian‐Reynier, C. (2009) · Psycho-Oncology · doi:10.1002/pon.1593 · Cited by 82 · see citing works
Computer Assisted Telephone Interviewing: Effects on Interviewers and Respondents
Groves, R. M., & Mathiowetz, N. A. (1984) · Public Opinion Quarterly · doi:10.1093/poq/48.1b.356 · Cited by 74 · see citing works
Thewes, B., Meiser, B., Duric, V. M., Stockler, M. R., Taylor, A., Stuart‐Harris, R. C., Links, M. J., Wilcken, N. R. C., McLachlan, S. A., Phillips, K., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70254-0 · Cited by 65 · see citing works
Güth, U., Huang, D. J., Schötzau, A., Zanetti‐Dällenbach, R., Holzgreve, W., Bitzer, J., & Wight, E. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604525 · Cited by 56 · see citing works
Wengström, Y., Aapro, M., di Priolo, S. L., Cannon, H., & Georgiou, V. (2007) · Breast · doi:10.1016/j.breast.2007.02.007 · Cited by 54 · see citing works
The Role of Parents and Family Members in ART Treatment Adherence: Evidence From Thailand
Knodel, J. E., Kespichayawattana, J., Saengtienchai, C., et al. (2009) · Research on Aging · doi:10.1177/0164027509348130 · Cited by 44 · see citing works
Gwadry-Sridhar, F. H., Manias, E., Zhang, Y., Roy, A. N., Yu-Isenberg, K. S., Hughes, D. A., & Nichol, M. B. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.02.021 · Cited by 42 · see citing works
Cutuli, B., Fourquet, A., Luporsi, É., et al. (2005) · PubMed · Cited by 39 · see citing works
Saint-Paul-de-Vence, de Saint-Paul-de-Vence, P. C., Organisation: LOb Conseils, & Gligorov, J. (2005) · ONCOLOGIE · doi:10.1007/s10269-005-0243-8 · Cited by 30 · see citing works
Patients and family care givers' experiences around highly active antiretroviral therapy (HAART)
Sacajiu, G. M., Raveis, V. H., & Selwyn, P. A. (2009) · AIDS Care · doi:10.1080/09540120902923113 · Cited by 11 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [18]18. Federation of French Cancer Centres (FNCLCC). Recommandations pour la pratique clinique de Saint-Paul-de-Vence: cancer du sein. Oncologie 2005; 7: 342-379.
Cited by
Sorted by citations
Murphy, C. C., Bartholomew, L. K., Carpentier, M. Y., Bluethmann, S. M., & Vernon, S. W. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2114-5 · Cited by 708 · see citing works
Understanding tamoxifen adherence in women with breast cancer: A qualitative study
Moon, Z., Moss‐Morris, R., Hunter, M. S., & Hughes, L. D. (2017) · British Journal of Health Psychology · doi:10.1111/bjhp.12266 · Cited by 112 · see citing works
Huiart, L., Bouhnik, A.-D., Rey, D., Tarpin, C., Cluze, C., Bendiane, M. K., Viens, P., & Giorgi, R. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.03.004 · Cited by 97 · see citing works
Self-citationSheppard, V. B., Faul, L. A., Luta, G., Clapp, J. D., Yung, R. L., Wang, J. H.-Y., Kimmick, G., Isaacs, C., Tallarico, M., Barry, W. T., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.7367 · Cited by 91 · see citing works
Hurtado-de-Mendoza, A., Cabling, M. L., Lobo, T., Dash, C., & Sheppard, V. B. (2016) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.03.006 · Cited by 79 · see citing works
Cahir, C., Guinan, E., Dombrowski, S. U., Sharp, L., & Bennett, K. (2015) · Patient Education and Counseling · doi:10.1016/j.pec.2015.05.013 · Cited by 84 · see citing works
Toivonen, K., Williamson, T., Carlson, L., Walker, L., & Campbell, T. (2020) · Cancers · doi:10.3390/cancers13010107 · Cited by 77 · see citing works
Finitsis, D. J., Vose, B. A., Mahalak, J. G., & Salner, A. L. (2019) · Psycho-Oncology · doi:10.1002/pon.4959 · Cited by 68 · see citing works
Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy
Kimmick, G., Edmond, S. N., Bosworth, H. B., Peppercorn, J., Marcom, P. K., Blackwell, K., Keefe, F. J., & Shelby, R. A. (2015) · The Breast · doi:10.1016/j.breast.2015.06.010 · Cited by 72 · see citing works
Ayres, L. R., Baldoni, A. D. O., Borges, A. P. D. S., & Pereira, L. R. L. (2014) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-013-9833-5 · Cited by 65 · see citing works
Neven, P., Markopoulos, C., Tanner, M., Marty, M., Kreienberg, R., Atkins, L., Franquet, A., Gnant, M., Neciosup, S., Tesarova, P., et al. (2014) · The Breast · doi:10.1016/j.breast.2014.02.009 · Cited by 53 · see citing works
Oncology providers’ perspectives on endocrine therapy prescribing and management
Wheeler, S., Roberts, M., Bloom, D., Reeder-Hayes, K., Espada, M., Peppercorn, J., Golin, C., & Earp, J. A. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s95594 · Cited by 31 · see citing works
- Authors
- Cluze, C., Rey, D., Huiart, L., BenDiane, M. K., Bouhnik, A. D., Berenger, C., Carrieri, M. P., & Giorgi, R.
- Affiliations
- Inserm (FR)
- Aix-Marseille Université (FR)
- Corresponding author
- Cluze, C.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 23
- Issue
- 4
- Pages
- 882-890
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2160838279
- Cited by
- 133
- References
- 42
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 5 · 2023: 7 · 2022: 9 · 2021: 9 · 2020: 14 · 2019: 8 · 2018: 8 · 2017: 13 · 2016: 11 · 2015: 11 · 2014: 12 · 2013: 9 · 2012: 5
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- The Regional Council
- the Research Ministry
- the General Direction of Health
- The National Institute of Cancer
- Fondation de France
- Association pour la recherche sur le cancer
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Keywords
- tamoxifen, adjuvant endocrine therapy, breast cancer, premenopausal women, young women, treatment interruption, social support, patient information, treatment side effects, fear of cancer recurrence, patient-provider relationship
- MeSH terms
- Adult, Breast Neoplasms, Female, Humans, Drug Prescriptions, Prospective Studies, Tamoxifen, Chemotherapy, Adjuvant, Antineoplastic Agents, Hormonal, Aromatase Inhibitors, Medication Adherence, Self Report, Drug Substitution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
